Phibro Animal Health (NASDAQ:PAHC) Posts Earnings Results, Beats Estimates By $0.04 EPS

Phibro Animal Health (NASDAQ:PAHC) issued its quarterly earnings data on Wednesday. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04, FiscalAI reports. The firm had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%. Phibro Animal Health updated its FY 2026 guidance to 2.980-3.100 EPS.

Phibro Animal Health Stock Up 4.0%

NASDAQ PAHC traded up $2.26 on Wednesday, reaching $58.50. 300,750 shares of the stock traded hands, compared to its average volume of 260,342. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The company has a fifty day moving average price of $54.07 and a 200-day moving average price of $46.48. The company has a market cap of $2.37 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 0.86 and a beta of 0.61. Phibro Animal Health has a 12 month low of $19.00 and a 12 month high of $60.08.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 0.8%. Phibro Animal Health’s dividend payout ratio is 21.33%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $52.76, for a total transaction of $371,430.40. Following the transaction, the chief executive officer owned 74,760 shares of the company’s stock, valued at approximately $3,944,337.60. This represents a 8.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 281,600 shares of company stock valued at $14,334,853. 50.13% of the stock is currently owned by corporate insiders.

Institutional Trading of Phibro Animal Health

Hedge funds have recently added to or reduced their stakes in the business. Caitlin John LLC purchased a new position in Phibro Animal Health during the 4th quarter valued at about $266,000. Mackenzie Financial Corp increased its position in Phibro Animal Health by 7.1% during the 4th quarter. Mackenzie Financial Corp now owns 50,619 shares of the company’s stock valued at $1,895,000 after purchasing an additional 3,355 shares during the period. XTX Topco Ltd increased its position in Phibro Animal Health by 125.4% during the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company’s stock valued at $606,000 after purchasing an additional 9,032 shares during the period. Zacks Investment Management increased its position in Phibro Animal Health by 13.2% during the 4th quarter. Zacks Investment Management now owns 91,391 shares of the company’s stock valued at $3,414,000 after purchasing an additional 10,642 shares during the period. Finally, VARCOV Co. purchased a new position in Phibro Animal Health during the 4th quarter valued at about $672,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on PAHC shares. Citigroup started coverage on Phibro Animal Health in a research report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price objective for the company. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.